3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2024年6月30日) | 当連結会計年度 (2025年6月30日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 1,788,506 | 1,562,417 |
売掛金 | 232,721 | 175,281 |
商品 | 11,116 | 18,144 |
仕掛品 | 18,522 | 22,107 |
原材料及び貯蔵品 | 7,352 | 10,901 |
その他 | 41,965 | 80,052 |
貸倒引当金 | △4,558 | △4,098 |
流動資産合計 | 2,095,627 | 1,864,807 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 68,719 | 71,597 |
工具、器具及び備品 | 603,229 | 734,540 |
リース資産 | 191,342 | 57,660 |
建設仮勘定 | 95,278 | 1,292 |
減価償却累計額 | △626,692 | △580,138 |
有形固定資産合計 | 331,878 | 284,952 |
無形固定資産 | 17,476 | 12,810 |
投資その他の資産 | | |
投資有価証券 | 7,000 | 49,980 |
繰延税金資産 | 146,234 | 157,021 |
破産更生債権等 | - | 9,746 |
その他 | 5,183 | 5,034 |
貸倒引当金 | - | △9,746 |
投資その他の資産合計 | 158,417 | 212,036 |
固定資産合計 | 507,773 | 509,799 |
資産合計 | 2,603,401 | 2,374,607 |
負債の部 | | |
流動負債 | | |
買掛金 | 15,038 | 3,860 |
短期借入金 | 200,000 | 100,000 |
リース債務 | 14,959 | 7,011 |
未払金 | 187,910 | 97,802 |
未払法人税等 | 26,233 | 16,405 |
賞与引当金 | 86,351 | 89,257 |
その他 | 102,264 | 135,605 |
流動負債合計 | 632,757 | 449,943 |
固定負債 | | |
リース債務 | 11,344 | 3,457 |
資産除去債務 | 12,585 | 12,609 |
固定負債合計 | 23,930 | 16,066 |
負債合計 | 656,688 | 466,009 |
純資産の部 | | |
株主資本 | | |
資本金 | 1,487,719 | 1,488,979 |
資本剰余金 | 6,118 | 7,378 |
利益剰余金 | 417,317 | 585,003 |
自己株式 | △167 | △166,586 |
株主資本合計 | 1,910,988 | 1,914,775 |
その他の包括利益累計額 | | |
為替換算調整勘定 | △18,026 | △24,171 |
その他の包括利益累計額合計 | △18,026 | △24,171 |
新株予約権 | 53,750 | 17,993 |
純資産合計 | 1,946,713 | 1,908,597 |
負債純資産合計 | 2,603,401 | 2,374,607 |
E3007160900ヒューマン・メタボローム・テクノロジーズ株式会社Human Metabolome Technologies, Inc.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-07-012025-06-30FY2025-06-302023-07-012024-06-302024-06-301falsefalsefalse609002025-06-30jppfs_cor:TreasuryStockMember609002024-07-012025-06-30jppfs_cor:TreasuryStockMember609002024-06-30jppfs_cor:TreasuryStockMember609002023-07-012024-06-30jppfs_cor:TreasuryStockMember609002023-06-30jppfs_cor:TreasuryStockMember609002025-06-30jppfs_cor:SubscriptionRightsToSharesMember609002024-07-012025-06-30jppfs_cor:SubscriptionRightsToSharesMember609002024-06-30jppfs_cor:SubscriptionRightsToSharesMember609002024-07-012025-06-30jppfs_cor:ValuationAndTranslationAdjustmentsMember609002024-07-012025-06-30jppfs_cor:ForeignCurrencyTranslationAdjustmentMember609002024-07-012025-06-30jppfs_cor:ShareholdersEquityMember609002024-07-012025-06-30jppfs_cor:RetainedEarningsMember609002024-07-012025-06-30jppfs_cor:CapitalSurplusMember609002024-07-012025-06-30jppfs_cor:CapitalStockMember609002024-06-30jppfs_cor:ValuationAndTranslationAdjustmentsMember609002024-06-30jppfs_cor:ForeignCurrencyTranslationAdjustmentMember609002025-06-30jppfs_cor:CapitalStockMember609002024-06-30jppfs_cor:ShareholdersEquityMember609002024-06-30jppfs_cor:RetainedEarningsMember609002024-06-30jppfs_cor:CapitalSurplusMember609002024-06-30jppfs_cor:CapitalStockMember609002023-07-012024-06-30jppfs_cor:ValuationAndTranslationAdjustmentsMember609002023-07-012024-06-30jppfs_cor:ForeignCurrencyTranslationAdjustmentMember609002023-07-012024-06-30jppfs_cor:ShareholdersEquityMember609002023-07-012024-06-30jppfs_cor:RetainedEarningsMember609002023-07-012024-06-30jppfs_cor:CapitalSurplusMember609002023-07-012024-06-30jppfs_cor:CapitalStockMember609002023-06-30jppfs_cor:ValuationAndTranslationAdjustmentsMember609002023-06-30jppfs_cor:ForeignCurrencyTranslationAdjustmentMember609002023-06-30jppfs_cor:ShareholdersEquityMember609002023-06-30jppfs_cor:RetainedEarningsMember609002023-06-30jppfs_cor:CapitalSurplusMember609002023-06-30jppfs_cor:CapitalStockMember609002025-06-30jppfs_cor:ValuationAndTranslationAdjustmentsMember609002025-06-30jppfs_cor:ForeignCurrencyTranslationAdjustmentMember609002025-06-30jppfs_cor:ShareholdersEquityMember609002025-06-30jppfs_cor:RetainedEarningsMember609002025-06-30jppfs_cor:CapitalSurplusMember609002023-06-30jppfs_cor:SubscriptionRightsToSharesMember609002023-07-012024-06-30jppfs_cor:SubscriptionRightsToSharesMember609002025-08-08609002025-06-30609002024-07-012025-06-30609002024-06-30609002023-07-012024-06-30609002023-06-30609002025-06-30jpcrp_cor:ReportableSegmentsMember609002024-07-012025-06-30jpcrp_cor:ReportableSegmentsMember609002024-06-30jpcrp_cor:ReportableSegmentsMember609002023-07-012024-06-30jpcrp_cor:ReportableSegmentsMember609002025-06-30tse-acedjpfr-60900:ResearchsupportAnalysisReportableSegmentsMember609002025-06-30tse-acedjpfr-60900:HealthcareAnalysisReportableSegmentsMember609002024-07-012025-06-30tse-acedjpfr-60900:ResearchsupportAnalysisReportableSegmentsMember609002024-07-012025-06-30tse-acedjpfr-60900:HealthcareAnalysisReportableSegmentsMember609002024-06-30tse-acedjpfr-60900:ResearchsupportAnalysisReportableSegmentsMember609002024-06-30tse-acedjpfr-60900:HealthcareAnalysisReportableSegmentsMember609002023-07-012024-06-30tse-acedjpfr-60900:ResearchsupportAnalysisReportableSegmentsMember609002023-07-012024-06-30tse-acedjpfr-60900:HealthcareAnalysisReportableSegmentsMemberiso4217:JPYxbrli:pure